VTV THERAPEUTICS INC- CL A (VTVT) Stock Price, Quote, News and Overview
NASDAQ:VTVT - Nasdaq - US9183852048 - Common Stock - Currency: USD
VTVT Quote, Performance and Key Statistics
NASDAQ:VTVT (5/22/2025, 8:00:02 PM)
19.45
-0.54 (-2.7%)
The current stock price of VTVT is 19.45 USD. In the past month the price decreased by -13.56%. In the past year, price decreased by -29.83%.
VTVT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.77 | 322.91B | ||
| AMGN | AMGEN INC | 13.1 | 146.19B | ||
| GILD | GILEAD SCIENCES INC | 13.79 | 132.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.47 | 64.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.59B | ||
| ARGX | ARGENX SE - ADR | 99.05 | 35.50B | ||
| ONC | BEIGENE LTD-ADR | 5.93 | 25.74B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.73B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.14B | ||
| BIIB | BIOGEN INC | 7.98 | 18.51B |
Related stock screener links
About VTVT
Company Profile
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 23 full-time employees. The company went IPO on 2015-07-30. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Company Info
VTV THERAPEUTICS INC- CL A
3980 Premier Dr, Suite 310
High Point NORTH CAROLINA 27265 US
CEO: Stephen L. Holcombe
Employees: 23
Phone: 13368410300
VTV THERAPEUTICS INC- CL A / VTVT FAQ
What is the stock price of VTV THERAPEUTICS INC- CL A today?
The current stock price of VTVT is 19.45 USD. The price decreased by -2.7% in the last trading session.
What is the ticker symbol for VTV THERAPEUTICS INC- CL A stock?
The exchange symbol of VTV THERAPEUTICS INC- CL A is VTVT and it is listed on the Nasdaq exchange.
On which exchange is VTVT stock listed?
VTVT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VTV THERAPEUTICS INC- CL A stock?
8 analysts have analysed VTVT and the average price target is 36.21 USD. This implies a price increase of 86.17% is expected in the next year compared to the current price of 19.45. Check the VTV THERAPEUTICS INC- CL A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VTV THERAPEUTICS INC- CL A worth?
VTV THERAPEUTICS INC- CL A (VTVT) has a market capitalization of 62.05M USD. This makes VTVT a Micro Cap stock.
How many employees does VTV THERAPEUTICS INC- CL A have?
VTV THERAPEUTICS INC- CL A (VTVT) currently has 23 employees.
What are the support and resistance levels for VTV THERAPEUTICS INC- CL A (VTVT) stock?
VTV THERAPEUTICS INC- CL A (VTVT) has a support level at 19.44 and a resistance level at 20.93. Check the full technical report for a detailed analysis of VTVT support and resistance levels.
Is VTV THERAPEUTICS INC- CL A (VTVT) expected to grow?
The Revenue of VTV THERAPEUTICS INC- CL A (VTVT) is expected to decline by -100% in the next year. Check the estimates tab for more information on the VTVT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VTV THERAPEUTICS INC- CL A (VTVT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VTVT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VTVT, evaluating the profitability, health, valuation and growth aspects
- VTV THERAPEUTICS INC- CL A (VTVT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VTV THERAPEUTICS INC- CL A (VTVT) Sales and EPS estimates to see what analysts future expectations are.
- VTV THERAPEUTICS INC- CL A (VTVT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VTV THERAPEUTICS INC- CL A (VTVT) Insider and Institutional Ownership to learn about the owners and their transactions.
- VTV THERAPEUTICS INC- CL A (VTVT) Stock Chart to make your own analysis
- VTV THERAPEUTICS INC- CL A (VTVT) Latest news and press-releases to stay up to date.
Does VTV THERAPEUTICS INC- CL A (VTVT) stock pay dividends?
VTVT does not pay a dividend.
When does VTV THERAPEUTICS INC- CL A (VTVT) report earnings?
VTV THERAPEUTICS INC- CL A (VTVT) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of VTV THERAPEUTICS INC- CL A (VTVT)?
VTV THERAPEUTICS INC- CL A (VTVT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.54).
What is the Short Interest ratio of VTV THERAPEUTICS INC- CL A (VTVT) stock?
The outstanding short interest for VTV THERAPEUTICS INC- CL A (VTVT) is 1.28% of its float. Check the ownership tab for more information on the VTVT short interest.
VTVT Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to VTVT. When comparing the yearly performance of all stocks, VTVT is a bad performer in the overall market: 77.71% of all stocks are doing better.
VTVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VTVT. VTVT has a great financial health rating, but its profitability evaluates not so good.
VTVT Financial Highlights
Over the last trailing twelve months VTVT reported a non-GAAP Earnings per Share(EPS) of -4.54. The EPS decreased by -1963.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.25% | ||
| ROE | -151.34% | ||
| Debt/Equity | 0 |
VTVT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to VTVT. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 91.69% and a revenue growth -100% for VTVT